Abstract
We surveyed IL-21 receptor (IL-21R) in leukemia and lymphoma and found that follicular lymphoma cells showed exceptionally high IL-21R expression. Notably, IL-21 showed divergent effects depending on the cell origin: growth stimulation in Burkitt lymphoma cell lines and adult T cell leukemia/lymphoma cell lines but induction of apoptosis in B lymphoma cell lines with t(14;18)(q32;q21), a marker karyotype of follicular lymphoma. IL-21 activated caspase-8 and -3 and reduced mitochondrial membrane potential. More importantly, IL-21 decreased Bcl-2 expression but increased Bax expression. These results support a new therapeutic approach using the IL-21/IL-21R system in follicular lymphoma.
MeSH terms
-
Animals
-
Antineoplastic Agents / metabolism*
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use
-
Apoptosis* / drug effects
-
Caspase 3 / metabolism
-
Caspase 8 / metabolism
-
Cell Proliferation / drug effects
-
Dose-Response Relationship, Drug
-
Enzyme Activation
-
Humans
-
Interleukins / metabolism*
-
Interleukins / pharmacology
-
Interleukins / therapeutic use
-
Jurkat Cells
-
K562 Cells
-
Leukemia / drug therapy
-
Leukemia / enzymology
-
Leukemia / metabolism*
-
Leukemia / pathology
-
Lymphoma, Follicular / drug therapy
-
Lymphoma, Follicular / enzymology
-
Lymphoma, Follicular / metabolism*
-
Lymphoma, Follicular / pathology
-
Membrane Potential, Mitochondrial
-
Proto-Oncogene Proteins c-bcl-2 / metabolism
-
Receptors, Interleukin-21 / metabolism*
-
Recombinant Proteins / metabolism
-
Signal Transduction* / drug effects
-
Time Factors
-
Tumor Cells, Cultured
-
U937 Cells
-
bcl-2-Associated X Protein / metabolism
Substances
-
Antineoplastic Agents
-
Interleukins
-
Proto-Oncogene Proteins c-bcl-2
-
Receptors, Interleukin-21
-
Recombinant Proteins
-
bcl-2-Associated X Protein
-
Caspase 3
-
Caspase 8
-
interleukin-21